Chemomab Therapeutics Ltd. — Form D
Chemomab Therapeutics Ltd. of TEL AVIV, L3, a company, filed a Form D exempt-offering notice with the SEC on 2021-03-30. The offering totals $45.4M, of which $45.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-03-30
- Form: D
- Accession: 0001104659-21-043650
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $45.4M
- Amount sold: $45.4M
- Investors: 26
- Date of first sale: 2021-03-16
- Security types: equity
- Revenue range: $25,000,001 - $100,000,000
- SEC file number: 021-393952
Issuer
- Name: Chemomab Therapeutics Ltd.
- CIK: 0001534248
- Entity type: Corporation
- Jurisdiction: ISRAEL
- Address: KIRYAT ATIDIM, BUILDING 7, TEL AVIV, L3, 6158002
- Phone: 972-77-331-0156
Officers, directors & promoters (17)
| Name | Role | Location |
|---|
| Moses Charles Alan | Director | Tel Aviv, L3 |
| Nissim Charles Darvish | Director | Tel Aviv, L3 |
| Joel Michael Maryles | Director | Hashmonaim, L3 |
| Adi Mor George | Director | Tel Aviv, L3 |
| Stephen P Squinto | Director | New York, NY |
| Arnon Aharon | Executive Officer | Tel Aviv, L3 |
| Sigal Fatal | Executive Officer | Ramat Gan, L3 |
| Adi Mor George | Executive Officer | Tel Aviv, L3 |
| Neil Harris Cohen | Director | Cambridge, MA |
| Jill Harris Quigley | Director | Tel Aviv, L3 |
| Sigal Fattal | Executive Officer | Ramat Gan, L3 |
| Adi Mor | Director | Tel Aviv, L3 |
| Adi Mor | Executive Officer | Tel Aviv, L3 |
| Alan Charles Moses | Director | Tel Aviv, L3 |
| Matthew Frankel | Executive Officer | WATERTOWN, MA |
| Claude Charles Nicaise | Director | Cheshire, CT |
| Nissim Darvish | Director | Tel Aviv, L3 |
Other filings by this issuer (1)
More